Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Short-term Investments (2017 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Short-term Investments for 5 consecutive years, with $28.7 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 5.55% to $28.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, up 5.55% year-over-year, with the annual reading at $28.7 million for FY2025, 5.55% up from the prior year.
  • Short-term Investments hit $28.7 million in Q4 2025 for Integra Lifesciences Holdings, down from $35.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $81.7 million in Q2 2024 to a low of $27.2 million in Q4 2024.
  • Historically, Short-term Investments has averaged $45.5 million across 3 years, with a median of $35.7 million in 2025.
  • Biggest YoY gain for Short-term Investments was 5.55% in 2025; the steepest drop was 56.31% in 2025.
  • Year by year, Short-term Investments stood at $32.7 million in 2023, then fell by 16.84% to $27.2 million in 2024, then grew by 5.55% to $28.7 million in 2025.
  • Business Quant data shows Short-term Investments for IART at $28.7 million in Q4 2025, $35.7 million in Q3 2025, and $35.7 million in Q2 2025.